Stockscreener 앱 받기
0.7887
1.83%
0.0142
시간 외 거래:
.79
0.0013
+0.16%
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
NeuroSense (NRSN) director Pellizzari details option and share holdings - Stock Titan
NeuroSense Therapeutics (NRSN) CMO details option and warrant holdings - Stock Titan
NeuroSense (NRSN) director details options and restricted share holdings - Stock Titan
NeuroSense (NRSN) GM Hagit Binder details share, option and RSU holdings - Stock Titan
/C O R R E C T I O N -- NeuroSense/ - PR Newswire
Bull Bear: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingStop Loss & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference - PR Newswire
Neurosense Therapeutics Ltd - Reuters
NeuroSense Therapeutics (NRSNW) Projected to Post Quarterly Earnings on Wednesday - Defense World
Director at NeuroSense (NASDAQ: NRSN) discloses equity awards and vesting - Stock Titan
EPS Watch: Whats the fair value of NeuroSense Therapeutics Ltd stock2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Is United Therapeutics Corporation gaining market share2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug Opening: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2026 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Breakout Watch: Will NeuroSense Therapeutics Ltd Equity Warrant benefit from green energy policiesTrend Reversal & Consistent Return Investment Signals - baoquankhu1.vn
FOMO Trade: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2026 Top Gainers & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Published on: 2026-03-17 06:01:38 - baoquankhu1.vn
NeuroSense’s ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology - TipRanks
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - PR Newswire
Tangible book value per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50 - Defense World
Operating cash flow per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
NeuroSense Shareholders Approve Increase in Registered Share Capital - The Globe and Mail
NeuroSense "PrimeC" Market size expansion of Several Folds by 2034 - openPR.com
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Roth/MKM initiates NeuroSense stock with buy on ALS drug potential - Investing.com Nigeria
Roth/MKM initiates NeuroSense stock with buy on ALS drug potential By Investing.com - Investing.com South Africa
Neurosense Therapeutics Ltd. Presents Long-Term Survival Data for Primec in Amyotrophic Lateral Sclerosis - marketscreener.com
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - PR Newswire
Analysis Recap: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leadersMarket Sentiment Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Long-Term Data From PARADIGM Trial Suggest Survival Benefit With PrimeC in ALS - NeurologyLive
Buy Signal: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectationsSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn
Will NeuroSense Therapeutics Ltd. stock continue upward momentumJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - Naître et grandir
Insider Sell: What are the risks of holding NeuroSense Therapeutics Ltd Equity WarrantJuly 2025 Update & Capital Efficiency Focused Ideas - baoquankhu1.vn
Revenue Check: Whats the fair value of NeuroSense Therapeutics Ltd stockRisk Management & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Published on: 2026-03-06 17:33:43 - baoquankhu1.vn
NRSN SEC FilingsNeurosense Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Revenue Check: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2025 Technical Patterns & Verified Momentum Stock Ideas - baoquankhu1.vn
IANS - IANS
Book value per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
Buyback Watch: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right now2025 Market WrapUp & Verified Momentum Watchlists - baoquankhu1.vn
NRSN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Panic Selling: Is NeuroSense Therapeutics Ltd still a buy after recent gains2025 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Activity Recap: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowJuly 2025 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
Earnings Miss: What is VCICs valuation compared to sector2025 Momentum Check & Real-Time Price Movement Reports - baoquankhu1.vn
Gap Down: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesTrade Exit Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
Why is NeuroSense Therapeutics Ltd. stock going downMarket Volume Summary & Daily Risk Controlled Trade Plans - mfd.ru
What are NeuroSense Therapeutics Ltd. Equity Warrant’s recent SEC filings showingStop Loss & Weekly High Conviction Ideas - mfd.ru
ALS drug PrimeC cuts death risk by 65% - Longevity.Technology
Is NeuroSense Therapeutics Ltd. Equity Warrant stock safe for conservative investorsPortfolio Value Report & Long-Term Safe Investment Ideas - mfd.ru
Aug Chart Watch: Does NeuroSense Therapeutics Ltd Equity Warrant align with a passive investing strategyJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 14.7% – Time to Sell? - Defense World
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS - Finviz
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
NeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial - TipRanks
Published on: 2026-02-18 21:38:58 - baoquankhu1.vn
ALS trial: NeuroSense drug extends survival by 14 months, cuts deaths 65% - Stock Titan
Buyout Rumor: Whats the analyst consensus on Invesco Mortgage Capital IncPortfolio Gains Report & Weekly High Return Stock Forecasts - baoquankhu1.vn
How NeuroSense Therapeutics Ltd. stock reacts to global recession fearsJuly 2025 Short Interest & Verified Stock Trade Ideas - mfd.ru
NRSN Should I Buy - Intellectia AI
What are the risks of holding NeuroSense Therapeutics Ltd. Equity WarrantWeekly Earnings Recap & Reliable Volume Spike Trade Alerts - mfd.ru
NeuroSense Provides Business Update and Progress for the First Half of 2025 - Intellectia AI
NRSNW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):